<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02816710</url>
  </required_header>
  <id_info>
    <org_study_id>2016062501</org_study_id>
    <nct_id>NCT02816710</nct_id>
  </id_info>
  <brief_title>Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy</brief_title>
  <official_title>Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy of different intravitreal Conbercept injection therapy in the treatment
      of severe proliferative diabetic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the clinical effects of preoperative, intraoperative or preoperative combined with
      intraoperative intravitreal conbercept (IVC) injection in pars plana vitrectomy (PPV) with
      silicone oil tamponade for severe proliferative diabetic retinopathy (PDR). Methods. These
      patients were randomly assigned to three groups: Group 1 received an IVC injection 3 to 5
      days before surgery; Group 2 received an IVC injection at the end of surgery; and Group 3
      received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of
      PPV. Follow-up examinations were performed for at least six months after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected Visual Acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Surgery</measure>
    <time_frame>during the operation time</time_frame>
    <description>To evaluate the influence of these three methods to the final duration of surgery. We carefully estimated the time of the vitrectomy from insertion to extraction of the 23-gauge three-port trocars.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative Bleeding</measure>
    <time_frame>Time between the insertion and extraction of three 23-gauge vitrectomy ports</time_frame>
    <description>The grading criteria for intraoperative bleeding: Grade 1, spontaneous cessation of minor bleeding or bleeding that stopped by transient elevation of perfusion pressure; Grade 2, moderate bleeding requiring endodiathermy or broad blood clots formed far away from the bleeding site; Grade 3, thick blood clots exceeding half of the posterior pole or affecting the operation field.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Preretinal Blood</measure>
    <time_frame>postoperatively, up to 1 week</time_frame>
    <description>The grading criteria for postoperative preretinal blood: Grade 1, isolated blood clots within 10 disk area but without covering the posterior pole; Grade 2, broad blood clots exceeding 10 disk area regardless of involvement of the posterior pole; Grade 3, broad blood clots exceeding 10 disk area as well as involving the posterior pole. Maximal extent of preretinal blood within 1 week postoperatively was used for grading the extent of hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reabsorption Time of Blood</measure>
    <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
    <description>To monitor the reabsorption time of preretinal blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Vitreous Hemorrhage</measure>
    <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
    <description>Recurrent vitreous hemorrhage(VH) was referred to any new episode of VH occurring after one week postoperatively, dividing into early stage (≤ 4 weeks) and late stage (&gt; 4 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Intraoperative Electrocoagulation</measure>
    <time_frame>during the operation time</time_frame>
    <description>The number of times electrocoagulation, which was used to stop bleeding, was carefully counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neovascular Glaucoma (NVG)</measure>
    <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Retinal Detachment</measure>
    <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Reoperation</measure>
    <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
    <description>due to recurrent retinal detachment or unclear vitreous hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <condition>Tractional Retinal Detachment</condition>
  <arm_group>
    <arm_group_label>IVC Preoperative group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conbercept injection before vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVC Postoperative group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conbercept injection at the end of vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVC Pre- and Post-operative group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First conbercept injection before vitrectomy and second at the end of operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept</intervention_name>
    <description>Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.</description>
    <arm_group_label>IVC Postoperative group</arm_group_label>
    <arm_group_label>IVC Pre- and Post-operative group</arm_group_label>
    <arm_group_label>IVC Preoperative group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of either sex aged ≥ 18 years.

          2. Diagnosis of diabetes mellitus (type 1 or type 2);

          3. Active proliferative diabetic retinopathy was clinically evident;

          4. Study eyes required a vitrectomy and silicone oil tamponade due to vitreous hemorrhage
             with significant fibrous proliferation, tractional retinal detachment in the posterior
             pole or complicated retinal detachment, which can be detected by B-scan
             ultrasonography.

          5. Ability to give informed consent.

        Exclusion Criteria:

          1. Coexistent ocular disease that may interfere with visual outcome;

          2. Prior vitreoretinal surgery or anti-vascular endothelial growth factor (VEGF)
             pharmacotherapy in either eye;

          3. A macula-involving retinal detachment for &gt;6 months in the study eye;

          4. Iris or angle neovascularization and neovascular glaucoma;

          5. known allergy to any components of conbercept formulation

          6. severe external ocular infection;

          7. pregnancy or current oral contraceptive intake;

          8. usage of anticoagulant or antiplatelet therapy;

          9. preoperative or postoperative poor diabetes control [serum hemoglobin A1c (HbA1c)
             &gt;11.0%];

         10. uncontrolled systemic diseases, such as hypertension, cardiac diseases or presenting
             abnormal coagulation-associated blood diseases;

         11. &lt;6 months of follow-up post initial surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi Shen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <results_first_submitted>June 20, 2019</results_first_submitted>
  <results_first_submitted_qc>November 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 21, 2019</results_first_posted>
  <last_update_submitted>November 2, 2019</last_update_submitted>
  <last_update_submitted_qc>November 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Xi Shen</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>Conbercept</keyword>
  <keyword>Proliferative diabetic retinopathy</keyword>
  <keyword>Silicone oil tamponade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02816710/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02816710/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was performed in the department of Ophthalmology, Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine, between July 2016 and September 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IVC Preoperative Group</title>
          <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
        </group>
        <group group_id="P2">
          <title>IVC Postoperative Group</title>
          <description>Patients in this group received an IVC injection at the end of surgery.</description>
        </group>
        <group group_id="P3">
          <title>IVC Pre- and Post-operative Group</title>
          <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of pars plana vitrectomy (PPV).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IVC Preoperative Group</title>
          <description>Conbercept injection before vitrectomy
Conbercept: Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.</description>
        </group>
        <group group_id="B2">
          <title>IVC Postoperative Group</title>
          <description>Conbercept injection at the end of vitrectomy
Conbercept: Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.</description>
        </group>
        <group group_id="B3">
          <title>IVC Pre- and Post-operative Group</title>
          <description>First conbercept injection before vitrectomy and second at the end of operation.
Conbercept: Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.76" spread="13.47"/>
                    <measurement group_id="B2" value="53.97" spread="14.76"/>
                    <measurement group_id="B3" value="52.55" spread="14.62"/>
                    <measurement group_id="B4" value="52.44" spread="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c at time of surgery</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.12" spread="1.52"/>
                    <measurement group_id="B2" value="7.59" spread="1.36"/>
                    <measurement group_id="B3" value="7.88" spread="1.26"/>
                    <measurement group_id="B4" value="7.51" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 1 diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes (years)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.50" spread="5.16"/>
                    <measurement group_id="B2" value="12.86" spread="5.23"/>
                    <measurement group_id="B3" value="12.66" spread="5.24"/>
                    <measurement group_id="B4" value="13.37" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Study eye (right eye)</title>
          <units>eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous history of pan-retinal photocoagulation (PRP)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LogMAR Best Corrected Visual Acuity (BCVA)</title>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.95" spread="0.43"/>
                    <measurement group_id="B2" value="1.97" spread="0.37"/>
                    <measurement group_id="B3" value="1.98" spread="0.44"/>
                    <measurement group_id="B4" value="1.96" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lens status (pseudophakic)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative iris neovascularization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extent of vitreoretinal adhesion grade</title>
          <description>The extent of vitreoretinal adhesion was assessed based on a previous grading system: Grade 0, without any adhesion; Grade 1, focal adhesion in less than 3 sites; Grade 2, broad adhesion in more than 1 site or adhesion at the disc, macular, or vascular arcade; Grade 3, vitreoretinal adhesion extending to the periphery. Grade 3 is considered to be the worst outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best-corrected Visual Acuity</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVC Preoperative Group</title>
            <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>IVC Postoperative Group</title>
            <description>Patients in this group received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>IVC Pre- and Post-operative Group</title>
            <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Best-corrected Visual Acuity</title>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.45"/>
                    <measurement group_id="O2" value="1.29" spread="0.46"/>
                    <measurement group_id="O3" value="1.16" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Surgery</title>
        <description>To evaluate the influence of these three methods to the final duration of surgery. We carefully estimated the time of the vitrectomy from insertion to extraction of the 23-gauge three-port trocars.</description>
        <time_frame>during the operation time</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVC Preoperative Group</title>
            <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>IVC Postoperative Group</title>
            <description>Patients in this group received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>IVC Pre- and Post-operative Group</title>
            <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Surgery</title>
          <description>To evaluate the influence of these three methods to the final duration of surgery. We carefully estimated the time of the vitrectomy from insertion to extraction of the 23-gauge three-port trocars.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.41" spread="11.24"/>
                    <measurement group_id="O2" value="67.66" spread="15.15"/>
                    <measurement group_id="O3" value="57.86" spread="13.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Bleeding</title>
        <description>The grading criteria for intraoperative bleeding: Grade 1, spontaneous cessation of minor bleeding or bleeding that stopped by transient elevation of perfusion pressure; Grade 2, moderate bleeding requiring endodiathermy or broad blood clots formed far away from the bleeding site; Grade 3, thick blood clots exceeding half of the posterior pole or affecting the operation field.</description>
        <time_frame>Time between the insertion and extraction of three 23-gauge vitrectomy ports</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVC Preoperative Group</title>
            <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>IVC Postoperative Group</title>
            <description>Patients in this group received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>IVC Pre- and Post-operative Group</title>
            <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Bleeding</title>
          <description>The grading criteria for intraoperative bleeding: Grade 1, spontaneous cessation of minor bleeding or bleeding that stopped by transient elevation of perfusion pressure; Grade 2, moderate bleeding requiring endodiathermy or broad blood clots formed far away from the bleeding site; Grade 3, thick blood clots exceeding half of the posterior pole or affecting the operation field.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Preretinal Blood</title>
        <description>The grading criteria for postoperative preretinal blood: Grade 1, isolated blood clots within 10 disk area but without covering the posterior pole; Grade 2, broad blood clots exceeding 10 disk area regardless of involvement of the posterior pole; Grade 3, broad blood clots exceeding 10 disk area as well as involving the posterior pole. Maximal extent of preretinal blood within 1 week postoperatively was used for grading the extent of hemorrhage.</description>
        <time_frame>postoperatively, up to 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVC Preoperative Group</title>
            <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>IVC Postoperative Group</title>
            <description>Patients in this group received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>IVC Pre- and Post-operative Group</title>
            <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Preretinal Blood</title>
          <description>The grading criteria for postoperative preretinal blood: Grade 1, isolated blood clots within 10 disk area but without covering the posterior pole; Grade 2, broad blood clots exceeding 10 disk area regardless of involvement of the posterior pole; Grade 3, broad blood clots exceeding 10 disk area as well as involving the posterior pole. Maximal extent of preretinal blood within 1 week postoperatively was used for grading the extent of hemorrhage.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reabsorption Time of Blood</title>
        <description>To monitor the reabsorption time of preretinal blood.</description>
        <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVC Preoperative Group</title>
            <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>IVC Postoperative Group</title>
            <description>Patients in this group received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>IVC Pre- and Post-operative Group</title>
            <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Reabsorption Time of Blood</title>
          <description>To monitor the reabsorption time of preretinal blood.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.24" spread="4.33"/>
                    <measurement group_id="O2" value="12.23" spread="6.19"/>
                    <measurement group_id="O3" value="10.10" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Vitreous Hemorrhage</title>
        <description>Recurrent vitreous hemorrhage(VH) was referred to any new episode of VH occurring after one week postoperatively, dividing into early stage (≤ 4 weeks) and late stage (&gt; 4 weeks).</description>
        <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVC Preoperative Group</title>
            <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>IVC Postoperative Group</title>
            <description>Patients in this group received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>IVC Pre- and Post-operative Group</title>
            <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Vitreous Hemorrhage</title>
          <description>Recurrent vitreous hemorrhage(VH) was referred to any new episode of VH occurring after one week postoperatively, dividing into early stage (≤ 4 weeks) and late stage (&gt; 4 weeks).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>early vitreous hemorrhage</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>late vitreous hemorrhage</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no vitreous hemorrhge</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Intraoperative Electrocoagulation</title>
        <description>The number of times electrocoagulation, which was used to stop bleeding, was carefully counted.</description>
        <time_frame>during the operation time</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Intraoperative Electrocoagulation</title>
          <description>The number of times electrocoagulation, which was used to stop bleeding, was carefully counted.</description>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="1.26"/>
                    <measurement group_id="O2" value="3.00" spread="1.14"/>
                    <measurement group_id="O3" value="1.34" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neovascular Glaucoma (NVG)</title>
        <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVC Preoperative Group</title>
            <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>IVC Postoperative Group</title>
            <description>Patients in this group received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>IVC Pre- and Post-operative Group</title>
            <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neovascular Glaucoma (NVG)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Retinal Detachment</title>
        <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVC Preoperative Group</title>
            <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>IVC Postoperative Group</title>
            <description>Patients in this group received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>IVC Pre- and Post-operative Group</title>
            <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Retinal Detachment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Reoperation</title>
        <description>due to recurrent retinal detachment or unclear vitreous hemorrhage</description>
        <time_frame>follow up period, up to an average of 6 months after the operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IVC Preoperative Group</title>
            <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
          </group>
          <group group_id="O2">
            <title>IVC Postoperative Group</title>
            <description>Patients in this group received an IVC injection at the end of surgery.</description>
          </group>
          <group group_id="O3">
            <title>IVC Pre- and Post-operative Group</title>
            <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Reoperation</title>
          <description>due to recurrent retinal detachment or unclear vitreous hemorrhage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Systemic adverse events such as heart failure, myocardial infarction or acute cerebrovascular diseases and ocular adverse events like endophthalmitis or ocular toxicity were observed in all participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>IVC Preoperative Group</title>
          <description>Patients in this group received an intravitreal conbercept (IVC) injection 3 to 5 days before surgery.</description>
        </group>
        <group group_id="E2">
          <title>IVC Postoperative Group</title>
          <description>Patients in this group received an IVC injection at the end of surgery.</description>
        </group>
        <group group_id="E3">
          <title>IVC Pre- and Post-operative Group</title>
          <description>Patients in this group received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Xi Shen</name_or_title>
      <organization>Department of Ophthalmology, Ruijin Hospital Affiliated Shanghai Jiaotong University School of Medicine, 197 Ruijin Er Road, 200025, Shanghai, China.</organization>
      <phone>021-64370025</phone>
      <email>carl_shen2005@126.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

